| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 |
|---|---|---|---|---|---|---|---|---|
Revenue: | ||||||||
Healthcare | ||||||||
- | - | - | - | 145,963 | 133,178 | 100,386 | 93,640 | 106,853 |
Research | ||||||||
- | - | - | - | 21,853 | 19,744 | 20,329 | 8,333 | 1,079 |
Other | ||||||||
- | - | - | - | 10,697 | 13,656 | 8,786 | 9,521 | 11,090 |
Revenue | ||||||||
439,107 | 399,472 | 286,776 | 208,332 | 178,513 | 166,578 | 129,501 | 111,494 | 119,022 |
Cost of revenue: | ||||||||
Healthcare | ||||||||
- | - | - | - | 51,693 | 54,942 | 34,179 | 36,793 | 42,258 |
Research | ||||||||
- | - | - | - | 12,728 | 10,646 | 11,317 | 3,726 | 571 |
Other | ||||||||
- | - | - | - | 7,535 | 7,526 | 4,935 | 5,074 | 6,247 |
Cost of revenue | ||||||||
164,833 | 148,986 | 114,406 | 78,882 | 71,956 | 73,114 | 50,431 | 45,593 | 49,076 |
Gross profit | ||||||||
274,274 | 250,486 | 172,370 | 129,450 | 106,557 | 93,464 | 79,070 | 65,901 | 69,946 |
Operating expenses: | ||||||||
General and administrative | ||||||||
120,093 | 109,736 | 82,983 | 55,877 | 47,882 | 45,131 | 36,569 | 32,644 | 35,011 |
Sales and marketing | ||||||||
50,664 | 42,849 | 35,322 | 28,636 | 27,936 | 28,805 | 26,275 | 25,604 | 27,821 |
Credit loss expense | ||||||||
21,800 | 22,200 | 13,300 | 9,931 | 8,047 | 9,347 | 7,787 | 11,912 | 12,080 |
Research and development | ||||||||
13,994 | 11,206 | 11,101 | 8,355 | 7,111 | 7,396 | 7,338 | 4,664 | 5,698 |
Other charges | ||||||||
15,004 | 14,659 | 31,436 | 8,639 | 6,063 | 7,098 | 7,982 | 4,236 | 4,659 |
Goodwill impairment | ||||||||
- | - | - | - | - | - | - | - | 45,999 |
Total operating expenses | ||||||||
221,523 | 200,672 | 174,133 | 111,438 | 97,039 | 97,777 | 85,951 | 79,060 | 131,268 |
Income from operations | ||||||||
52,751 | 49,814 | -1,763 | 18,012 | 9,518 | -4,313 | -6,881 | -13,159 | -61,322 |
Other expense: | ||||||||
Other expense: | ||||||||
Interest expense | ||||||||
9,482 | 9,429 | 4,897 | 1,830 | 1,534 | - | - | - | - |
Gain (Loss) on Extinguishment of Debt | ||||||||
0 | 0 | -543 | 0 | 0 | - | - | - | - |
Loss on equity method investments | ||||||||
-1,298 | -246 | -384 | -287 | 0 | - | - | - | - |
Other non-operating income/(expense), net | ||||||||
-2,243 | 1,365 | -2,809 | -125 | -88 | - | - | - | - |
Total other expense, net | ||||||||
-13,023 | -8,310 | -8,633 | -2,242 | -1,622 | -7,793 | -223 | 52 | 144 |
Income before income taxes | ||||||||
39,728 | 41,504 | -10,396 | 15,770 | 7,896 | -12,106 | -7,104 | -13,107 | -61,178 |
(Provision for)/benefit from income taxes | ||||||||
9,884 | -370 | 6,747 | -37,667 | 468 | -2,313 | 215 | -905 | 244 |
Net income | ||||||||
29,844 | 41,874 | -17,143 | 53,437 | 7,428 | - | - | - | - |
Net loss attributable to noncontrolling interests | ||||||||
0 | -946 | -1,187 | 0 | 0 | - | - | - | - |
Net income/(loss) attributable to BioTelemetry, Inc. | ||||||||
- | - | - | - | 7,428 | - | - | - | - |
Net Income (Loss) Available to Common Stockholders, Basic | ||||||||
29,844 | 42,820 | -15,956 | 53,437 | - | -9,793 | -7,319 | -12,202 | -61,422 |
Other comprehensive income/(loss): | ||||||||
Foreign currency translation loss | ||||||||
- | - | - | - | -12 | - | - | - | - |
Unrealized holding gains/(losses) arising during the period | ||||||||
- | - | - | - | - | - | - | 16 | -24 |
Comprehensive income/(loss) attributable to BioTelemetry, Inc. | ||||||||
- | - | - | - | 7,416 | -9,793 | -7,319 | -12,186 | -61,446 |
Net income per common share: | ||||||||
Basic (in dollars per share) | ||||||||
0.88 | 1.31 | -0.53 | 1.91 | 0.27 | -0.37 | -0.29 | - | - |
Diluted (in dollars per share) | ||||||||
0.82 | 1.20 | -0.53 | 1.75 | 0.26 | -0.37 | -0.29 | - | - |
Basic and diluted (in dollars per share) | ||||||||
- | - | - | - | - | - | - | -0.49 | -2.51 |
Weighted average number of common shares outstanding: | ||||||||
Basic (in shares) | ||||||||
33,948 | 32,709 | 30,386 | 27,920 | 27,116 | 26,444 | 25,543 | - | - |
Dilutive common stock equivalents (in shares) | ||||||||
2,492 | 3,074 | 0 | 2,569 | 1,973 | - | - | - | - |
Diluted (in shares) | ||||||||
36,440 | 35,783 | 30,386 | 30,489 | 29,089 | 26,444 | 25,543 | - | - |
Basic and diluted (in shares) | ||||||||
- | - | - | - | - | - | - | 24,933 | 24,425 |
Anti-dilutive stock options and restricted stock units excluded from weighted average calculation (in shares) | ||||||||
- | - | - | - | 1,103 | - | - | - | - |